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a  b  s  t  r  a  c  t
Transcription  factor  NF-E2  p45-related  factor  2  (Nrf2, also  called  Nfe2l2),  a master  regulator  of  redox
homeostasis,  and  its  dominant  negative  regulator,  Kelch-like  ECH-associated  protein  1 (Keap1),  together
tightly control  the  expression  of  numerous  detoxifying  and  antioxidant  genes.  Nrf2  and  the  ‘antioxidant
response  element’  (ARE)-driven  genes  it  controls  are  frequently  upregulated  in pancreatic  cancer  and
correlate  with  poor survival.  Upregulation  of Nrf2 is, at least  in part,  K-Ras  oncogene-driven  and  con-
tributes  to  pancreatic  cancer  proliferation  and  chemoresistance.  In  this  review,  we  aim  to  provide  an
overview  of  Keap1–Nrf2  signalling  as  it relates  to pancreatic  cancer,  discussing  the  effects  of  inhibiting
Nrf2  or  Nrf2/ARE  effector  proteins  to  increase  chemosensitivity.
© 2015  Elsevier  Ltd.  All  rights  reserved.
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive
malignancy with the lowest survival rates and worst prognosis of
all gastrointestinal cancers. The tumour has a prominent stromal
component and is intrinsically chemoresistant. Additionally, PDAC
characteristically disseminates early in the clinical course, when
there are minimal symptoms, and the diagnosis is often reached at
an advanced stage of the disease. Surgical resection with or with-
out adjuvant chemotherapy can be indicated in localised disease,
but unfortunately recurrence is common due to the particularly
aggressive biology of this cancer.
The development of neoplastic disease, not least PDAC, is a com-
plex multistep process involving a variety of aberrant signalling
pathways which can reprogram energy metabolism, promote a
growth-permissive tumour microenvironment that helps sustain
proliferative signalling and replicative immortality, activate local
tissue invasion and distant metastasis (Hanahan and Weinberg,
2011). Somatic gene mutations show particular heterogeneity in
pancreatic cancer, and it is this understanding of the disease, in
the context of the limited benefits seen in PDAC clinical trials,
that underpins the increasing shift towards biology-tailored, per-
sonalised drug therapy (Chang et al., 2014). Urgent advances are
required to further unlock the complex biological mechanisms that
contribute to pancreatic cancer chemoresistance which might lead
to tractable drug targets.
Transcription factor nuclear factor erythroid 2 p45-related factor
2 (Nrf2, also called Nfe2l2) is known not only for its role in cancer
chemoprevention but, conversely, also in cancer cell chemoresis-
tance (Lau et al., 2008). Nrf2 forms part of the Keap1–Nrf2–ARE
oxidative stress response pathway, and has recently been identified
as a contributory factor both in pancreatic carcinogenesis, and in
chemoresistance against gemcitabine, amongst other anti-cancer
cytotoxics. In the present article we review the current understand-
ing of the Keap1–Nrf2–ARE pathway, with an overview of how
this system can become dysregulated, with a particular focus on
its relation to pancreatic cancer.
2. The Keap1–Nrf2–ARE pathway
Nrf2 provides one of the most versatile mechanisms of adapt-
ion to cellular oxidative stress. It is a master regulator of redox
homeostasis, and is widely expressed in human tissues, particu-
larly those continuously exposed to environmental toxins such as
the skin, lungs and the upper digestive tract. Together with NF-E2
p45, Nrf1, Nrf3, Bach1 and Bach2, Nrf2 is a member of the cap ‘n’
collar (CNC) family of transcription factors which share a common
basic-region leucine zipper (bZIP) structure that exists in its Neh1
domain (Zhang, 2006). The abundance of Nrf2 within the cell is
normally tightly restricted by a redox-sensitive E3 ubiquitin ligase
substrate adaptor called Keap1 (Kelch-like ECH-associated protein 1).
This regulator was originally identified by yeast two-hybrid anal-
ysis (Itoh et al., 1999), and was confirmed as a repressor by the
finding that Nrf2 accumulated in the nucleus and Nrf2-target genes
were upregulated in Keap1 gene knockout mice (Wakabayashi et al.,
2003). Moreover, knockdown of Keap1 in human cell lines simi-
larly increases expression of Nrf2-target genes (Devling et al., 2005;
Agyeman et al., 2012). In the cytoplasm, Keap1 may  be associ-
ated with the cytoskeleton and interacts with cullin-3 (via its BTB
domain) and the Neh2 domain of Nrf2 (via its Kelch-repeat domain)
(McMahon et al., 2003; Nioi and Hayes, 2004). In doing so, Keap1
facilitates Cul3-mediated ubiquitination of Nrf2 and subsequent
proteolytic destruction of the CNC-bZIP transcription factor by the
26S proteasome (Itoh et al., 1999; Zhang et al., 2004). Under normal
homeostatic conditions, when ubiquitination is unimpeded, Nrf2
has a short half-life of approximately 10–30 min  (Itoh et al., 2003).
Cysteine residues present in Keap1 function as redox sensors that
when modified by oxidation or adduction by electrophiles, cause
loss of Nrf2 ubiquitination. Once modified and inactive, the fate of
Keap1 is controversial, with a few authors suggesting that Nrf2 is
liberated from Keap1 (Itoh et al., 2003), while others suggest that
this does not occur (McMahon et al., 2006; Baird et al., 2013). In any
event, upon inactivation of Keap1, newly translated Nrf2 translo-
cates to the nucleus where it heterodimerizes with small Maf  (sMaf)
proteins before it binds DNA (Motohashi and Yamamoto, 2004).
Together, the Nrf2-sMaf protein heterodimer binds to a specific
DNA sequence, called the antioxidant response element (ARE), in
the promoter region of target genes (Itoh et al., 1997; Zhang, 2006).
By this mechanism, Nrf2 constitutes a unique redox regulator
whose activity can be increased in response to imbalances in nor-
mal  redox caused by oxidative and electrophilic stressors (Fig. A1).
2.1. Redox cellular stress
While living cells operate optimally within certain pH and
temperature limits, they also require optimal redox balance for
metabolic processes, and their ability to adapt rapidly to per-
turbations in homeostasis is essential for survival. Cells can be
threatened by reactive oxygen species (ROS) and by toxic secondary
metabolites generated from ROS-mediated cell damage, giving rise
to oxidative stress (Halliwell and Gutteridge, 2007). The latter
involves various deleterious processes that result from an imbal-
ance between antioxidant defences and excessive ROS (Turrens,
2003; Acharya et al., 2010). Resulting damage from oxidative stress,
if substantial, can lead to cell death unless adaptive processes are
implemented that can withstand the harmful effects. ROS com-
prises oxygen-derived molecules and free radicals which can arise
during normal metabolism (Turrens, 2003), and also during cell
proliferation or abnormal and stressful events, such as endoplas-
mic  reticulum (ER) stress or oncogenic transformation (Zhang and
Kaufman, 2008; Logsdon and Ji, 2013; Kong et al., 2013). More-
over, exogenous toxic environmental agents, such as chemotherapy
drugs and cigarette combustion products, may  also induce free
radicals (Hayes and McMahon, 2009; Ju et al., 2015).
2.2. Cytoprotection by ARE-driven genes
Upon translocation to the nucleus, Nrf2 can activate the tran-
scription of approximately 200 genes (Hayes and Dinkova-Kostova,
2014). The coordinated activation of target genes by Nrf2 is
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possible because of specific antioxidant response element (ARE)
sequences within each gene regulatory region, and these genes
encode for enzymes that contribute a wide range of cytoprotective
functions including regulation of antioxidant and drug detoxifi-
cation systems, NADPH regeneration, modulation of intermediary
metabolism, and regulation of the proteasome (see Fig. A2). Nor-
mal  cells rely on the Keap1–Nrf2–ARE pathway to handle redox
stress and defend against cellular damage. Indeed, Nrf2/ARE can
be activated by relatively non-toxic dietary compounds, such as
isothiocyanates, coumarins and phenolic antioxidants, which pro-
tects against subsequent exposure to harmful xenobiotics (Hayes
et al., 2000; Higgins et al., 2009; McWalter et al., 2004). For example,
pre-treatment of fibroblasts with the isothiocyanate sulforaphane,
produced by hydrolysis of glucoraphanin (present in cruciferous
vegetables such as broccoli), elicits an Nrf2-mediated adaptive
response that markedly increases intracellular levels of glutathione
(Hayes et al., 2008; Higgins et al., 2009). A brief overview of
the major Nrf2/ARE target genes and Nrf2 effector proteins is
described, with a focus on those known to be upregulated in
PDAC.
The glutathione and thioredoxin systems are the two  major
thiol-dependent endogenous antioxidant systems found in mam-
malian cells which scavenge reactive oxygen and nitrogen species
(Lu and Holmgren, 2014). Nrf2/ARE tightly regulate glutathione
by controlling the expression of the glutamate–cysteine ligase
catalytic (GCLC) and modifier (GCLM) subunits that combine to
form a heterodimer which catalyses the rate-limiting step in glu-
tathione biosynthesis. Nrf2/ARE also control the expression of
glutathione peroxidase (GPX2 gene) and glutathione reductase
(GSR1 gene), which together ensure intracellular levels of peroxides
are reduced and, using NADPH as a cofactor, oxidised glutathione
(GSSG) is returned to its reduced (GSH) state. Nrf2/ARE signalling
also controls the expression of cytosolic thioredoxin (TXN1 gene),
thioredoxin reductase (TXNRD1 gene), and sulfiredoxin (SRXN1
gene), all of which reduce oxidised protein thiols (Lu and Holmgren,
2014). In PDAC, the glutathione-based antioxidant system con-
tributes to gemcitabine resistance (Kim et al., 2014), and the
thioredoxin-based system supports cancer cell survival (Yan et al.,
2009).
Cellular elimination of xenobiotics is another important func-
tion of Nrf2/ARE-mediated signalling which occurs through the
transport of exogenous compounds out of the cell by multi-
drug-resistance-associated protein transporters (MRPs), or else by
intracellular drug metabolism. Expression of drug efflux trans-
porter genes is dysregulated in PDAC and thought to contribute
to chemoresistance by increased movement of anti-cancer drugs
out of the cancer cell (Mohelnikova-Duchonova et al., 2013). Mem-
bers of the ATP-binding cassette subfamily C (e.g. ABCC1,  ABCC3
and ABCC5 genes) are under Nrf2/ARE-mediated regulation, and
increased expression of these transporters in PDAC is associated
with a poor treatment response (Mohelnikova-Duchonova et al.,
2013). The basal and inducible expression of several phase I and
phase II drug detoxification enzymes by the Nrf2/ARE system
is widely recognised, and over expression of aldo–keto reduc-
tase (Chung et al., 2012; Li et al., 2013; Zhang et al., 2014; Yi
and Oh, 2015), aldehyde dehydrogenase (Yi and Oh, 2015; Singh
et al., 2015), and NQO1 (Awadallah et al., 2008) have been identi-
fied in several PDAC cell lines. Many of these drug-metabolizing
enzymes as well as the antioxidant systems require NADPH as
a cofactor, and Nrf2 regulates all four of the NADPH-generating
enzymes. Thus, Nrf2 activity ensures that the expression of antiox-
idant and detoxification enzymes is coupled with a supply of the
necessary cofactors. Moreover, whilst NADPH is required for the
biosynthesis of lipids and nucleotides, Nrf2 also regulates criti-
cal enzymes in major metabolic pathways, such as the pentose
phosphate pathway (PPP) and fatty acid synthesis, and in doing so
influences the biosynthesis of carbohydrates, lipids, nucleic acids,
and amino acids (for a detailed review see ‘Hayes and Dinkova-
Kostova, 2014’). In the context of oncogenic transformation and
proliferation, wherein cancer cells consume large quantities of
nutrients and maintain high levels of anabolism, Nrf2/ARE sig-
nalling has been shown to redirect glucose and glutamine into
anabolic pathways (Mitsuishi et al., 2012) and in this way  could
support cell proliferation in pancreatic carcinogenesis. Of particu-
lar importance to PDAC, the PPP has been found to be an essential
fuel source for rapid K-Ras-induced cell proliferation (Weinberg
et al., 2010).
Heme oxygenase-1 (HO-1), which catalyzes the first and rate-
limiting enzymatic step of heme degradation, is another important
cytoprotective enzyme encoded by an ARE-target gene with antiox-
idant, antiapoptotic, proliferative and pro-angiogenic properties
(Dunn et al., 2014). In human PDAC tissue, HO-1 is upregulated
(Berberat et al., 2005), and is discussed in more detail later. Another
function of Nrf2/ARE-driven signalling is to increase proteasomal
gene expression (e.g. s5a/psmd4 and alpha5/psma5). Proteasomal
activity is important for the removal of damaged and misfolded
proteins that otherwise could impair cell function (Kwak et al.,
2003). Nrf2 inhibition in tumour cells down-regulates the pro-
teasome, rendering such cells more susceptible to apoptosis (Arlt
et al., 2009). Lastly, evidence also exists that Nrf2 combats ER stress
(Meakin et al., 2014), possibly by orchestrating adaption to oxida-
tive stress (Cullinan and Diehl, 2004), and since correct processing
and secretion proteins is an important function of the exocrine and
endocrine pancreas, this may  be an important contribution of the
CNC-bZIP transcription factor for pancreatic function in both health
and disease (Sah et al., 2014).
2.3. Endogenous Nrf2 upregulatory mechanisms
Whilst Nrf2 activity is usually tightly controlled, there are sev-
eral endogenous ways by which Nrf2 activity may  be altered.
Firstly, KEAP1 epigenetic silencing by hypermethylation of the pro-
moter gives rise to Nrf2 upregulation (Wang et al., 2008; Zhang
et al., 2010; Muscarella et al., 2011). Similarly, and by way  of
contrast, epigenetic alterations to the NFE2L2 promoter, such as
promoter hypermethylation or single nucleotide polymorphisms,
have been found to substantially repress Nrf2 transcription and
activity (Yu et al., 2010; Suzuki et al., 2013). Direct mutations
of the NFE2L2 gene resulting in modification of those residues in
Nrf2 that interact with Keap1, permanently increase the activity
of the CNC-bZIP transcription factor (Hayes and McMahon, 2009).
Functional KEAP1 mutations (i.e. missense, frameshift and homozy-
gous deletion of KEAP1)  which arise in a number of cancers (i.e.
lung, gallbladder, breast), result in up-regulated Nrf2–ARE gene
transcription (Singh et al., 2006; Shibata et al., 2008). There is an
extensive and increasing list of factors known to trans-activate
the NFE2L2 gene leading to overexpression of Nrf2 (Hayes and
Dinkova-Kostova, 2014); amongst these are oncogenes important
in pancreatic cancer, which will be discussed in more detail later.
Beyond translation, Keap1 is silenced through mechanisms such as
microRNA repression (i.e. miR-141, miR-200a) (Eades et al., 2011),
or autophagosome regulation (i.e. p62/SQSTM1) (Taguchi et al.,
2012), resulting in ineffective Nrf2 repression. Post-translational
modifications of Keap1 can inhibit its association with the Cul3
ubiquitin ligase, causing Nrf2 saturation of Keap1, thereby allowing
nuclear import of newly formed Nrf2. More specifically, alter-
ations to particular Keap1 cysteine residues (e.g. Cys-273, Cys-288
and Cys-151) which act as sensors for electrophiles have been
identified as key functional sites which, when modified, block
Keap1-mediated ubiquitylation and turn-over of Nrf2, as has the
formation of a disulphide bond between residues Cys-226 and
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Cys-613 (Wakabayashi et al., 2004; Zhang and Hannink, 2003;
Fourquet et al., 2010; Hourihan et al., 2013).
Other cytoplasmic proteins may  also interfere with Keap1–Nrf2
interaction. Indeed, there exist several proteins (e.g. PALB2, PGAM5,
WTX) that are known to bind the Kelch domain of Keap1, pre-
venting Keap1–Nrf2 association (Hayes and Dinkova-Kostova,
2014). Additionally, Keap1 is not the only negative regulator
of Nrf2, and other proteins (e.g. !-TrCP) can mediate Nrf2 ubi-
quitination through other binding sites on Nrf2 (Rada et al.,
2011; Chowdhry et al., 2013). Finally, phosphorylation can pre-
vent Keap1–Nrf2 interaction and thereby increase Nrf2 nuclear
translocation (Zipper and Mulcahy, 2000). For example, during
ER stress PERK phosphorylates Nrf2 which evades proteaso-
mal  destruction and translocates to the nucleus, and thereby
switching on cytoprotective ARE-driven genes (Cullinan et al.,
2003).
3. Dysregulation of Keap1–Nrf2 signalling in pancreatic
cancer
The Keap1–Nrf2–ARE pathway is vital in protecting normal
cells from oxidative stress, but in cells harbouring activated onco-
genes, upregulation of the ARE-gene battery may  offer survival and
proliferative advantages within the metabolic cancer microenvi-
ronment, and help withstand attack from immune regulation or
cytotoxic chemotherapy compounds (Hayes and McMahon, 2009;
Lau et al., 2008; Homma  et al., 2009). Several forms of cancer,
including lung (Padmanabhan et al., 2006) and endometrial can-
cers (Chen et al., 2010), appear to hijack the defence provided by
ARE-driven genes through constitutive upregulation of Nrf2, and
there is growing evidence to support an important role for the
Keap1–Nrf2–ARE pathway in pancreatic cancer. A review of the
literature investigating Nrf2 signalling in PDAC is discussed below,
and summarised in Fig. A3.
3.1. ARE-driven gene expression is increased in pancreatic cancer
Evidence for the contributory role of the Nrf2–ARE system
in PDAC appears to have first emerged from the study of cell
lines and clinical samples, of which the latter have consis-
tently shown moderate to strong immunohistochemical staining
of malignant epithelium for proteins regulated via ARE sequences
in their gene promoters. A prototypical Nrf2 downstream pro-
tein, NQO1 (NAD(P)H:quinone oxidoreductase 1), was found to be
over-expressed ten-fold compared to normal human pancreatic tis-
sue (Logsdon et al., 2003). Strong immunohistochemical staining
for NQO1 has also been demonstrated in premalignant pancreatic
dysplastic lesions, known as Pancreatic Intraepithelial Neoplasias
(PanINs), suggesting that it is frequently activated early in pan-
creatic carcinogenesis (Awadallah et al., 2008; Lewis et al., 2005).
However, specificity for PDAC may  be poor since NQO1 is also
over-expressed in non-tumorous pancreatic specimens from smok-
ers, and in pancreatitis tissue (Lewis et al., 2005; Lyn-Cook et al.,
2006). There does not appear to be an increase in NQO1 gene poly-
morphisms in pancreatic cancer resections compared to normal
pancreatic tissue (Lyn-Cook et al., 2006). DeNicola et al. demon-
strated that Nrf2-deficient murine PanINs were negative for Nqo1
in an Nfe2l2 gene knockout model, supporting the notion that Nrf2
plays a dominant role in upregulating the protein in pancreatic
cancer (DeNicola et al., 2011). Likewise, another Nrf2–ARE down-
stream protein, AKR1B10 (aldo–keto reductase family 1 member
b10), has been found to be over-expressed in PDAC, and also in the
majority of PanIN lesions. Amongst well- and moderately differ-
entiated pancreatic cancer specimens, approximately 70 per cent
were found to over-expressed AKR1B10, compared to surrounding
morphologically normal ducts (Chung et al., 2012). This Nrf2-target
protein is of particular interest because its inhibition both impedes
pancreatic carcinogenesis, and leads to a reduction in activated
K-Ras protein (Li et al., 2013).
3.2. Nrf2 expression is higher than Keap1 and correlates with
poor survival
Several authors have demonstrated a direct increase of Nrf2
protein levels in human pancreatic cancer tissue, particularly in
the cytoplasm of the malignant epithelial cells (DeNicola et al.,
2011; Hong et al., 2010; Lister et al., 2011). Specifically, Lister
et al. found that the majority of pancreatic cancer specimens
(48 of 57 specimens) showed strong Nrf2 cytoplasmic staining
by immunocytochemistry, compared to the relatively infrequent
strong staining amongst benign ducts (four of 21 specimens).
No difference in nuclear staining was detected between cancers
and benign ducts (Lister et al., 2011). Hong et al. similarly found
frequent strong cytoplasmic Nrf2 staining in pancreatic cancer
specimens, but in contrast to Lister et al., a higher proportion of
nuclear staining was detected in PDAC compared to normal tissue.
Importantly, following pancreatic resection, an increase in nuclear
Nrf2 expression was  found to correlate with a significant reduction
in overall survival (Soini et al., 2014). Levels of cytoplasmic Keap1
are higher in human PDAC tissue than in benign ductal epithelium,
but still only detectable in ∼30%, suggesting that Keap1 transcrip-
tion remains relatively low compared to the much higher Nrf2
levels (Lister et al., 2011).
3.3. Absence of KEAP1 or NFE2L2 gene mutations in pancreatic
cancer
DeNicola et al. tested for somatic mutations in KRAS, NFE2L2
and KEAP1 genes by sequencing over 100 human pancreatic can-
cer resection specimens. The vast majority had KRAS mutations, in
keeping with the literature. There were no NFE2L2 mutations in this
series and just three nonsynonymous KEAP1 mutations (see supple-
mentary Fig. 14b of paper by DeNicola et al.), giving a mutational
prevalence of approximately one per cent, which is considerably
lower than that observed in other cancers (DeNicola et al., 2011).
In corroboration with this, a publically available transcript database
that contained 24 PDAC cases revealed no KEAP1 or NFE2L2 muta-
tions (Lister et al., 2011; Jones et al., 2008). Therefore, unlike biliary
tract cancers that frequently contain functional KEAP1 mutations
(Shibata et al., 2008), over-expression of Nrf2 in pancreatic cancer
does not appear to be a consequence of somatic gene mutations in
NFE2L2 or in KEAP1.
3.4. Increased Nrf2 activity in pancreatic carcinogenesis
During pancreatic carcinogenesis, Nrf2 activity is increased and
this may  also be important during oncogenic transformation in
chronic pancreatitis.
Using a conditional transgenic K-Ras knock-in mouse PDAC
model, Nrf2 deletion in these mice has been shown to result in
fewer PanINs, reduced cellular proliferation, and reduced tumour
burden, whilst at the same time maintaining elevated DNA oxida-
tion (DeNicola et al., 2011). The findings of DeNicola et al. may  at
first appear paradoxical; that ROS, which are traditionally consid-
ered to contribute to carcinogenesis through mutagenic oxidation
of DNA, are repressed in pancreatic carcinogenesis by activation
of the ROS-detoxification program. The explanation, however, lies
in a novel finding of oncogene-mediated Nrf2 activation. Firstly,
DeNicola et al. demonstrated that expression of K-Ras,  B-Raf and
Myc oncogenic alleles in murine embryonic fibroblasts increased
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Nfe2l2 transcription and thus Nrf2 activity in a Keap1-independent
manner. This is not a universal feature of oncogenes, as demon-
strated by the inability of activated Notch 1 and ˇ-Catenin to
upregulate the Nrf2–ARE system (DeNicola et al., 2011). DeNicola
et al. demonstrated that K-Ras and B-Raf stimulated the binding
of Jun and Myc  (of the MAP  kinase signalling pathway) to the
Nfe2l2 gene promoter; thereby switching on the Nrf2–ARE sys-
tem.
TP53INP1 (tumour protein 53-incuded protein 1) is a stress-
induced p53 (protein 53)  target gene that induces cell growth
arrest and apoptosis by modulating p53 activity, and contributes
to the p53-driven oxidative stress response. In human tissue,
TP53INP1 expression is found in normal pancreas and low grade
dysplasic lesions (PanIN-1A), but only half of PanIN-2s express
this protein and it is absent in high grade lesions (PanIN-3) and
in PDAC, which suggests that expression of TP53INP1 is typ-
ically lost early in pancreatic carcinogenesis (Gironella et al.,
2007). Not only has loss of TP53INP1 been shown to accelerate
murine PanIN formation, this loss is associated with increased
levels of Nrf2 (Al Saati et al., 2013). It is known that absent
TP53INP1 gives rise to diminished antioxidant activity, which
can arise through both p53-dependent and p53-independent sig-
nalling mechanisms (Cano et al., 2009). Either way, it is likely
that secondary increased intracellular ROS levels as a consequence
of diminished TP53INP1 results in oxidation of Keap1 residues
thereby promoting nuclear translocation of Nrf2. There are, how-
ever, several points of crosstalk between p53 and Nrf2 signalling
(Rotblat et al., 2012) which may  provide an alternative mecha-
nism for increased Nrf2 levels as a result of TP53INP1 deficiency
in pancreatic cancer.
It has long been recognised that chronic pancreatitis (CP),
which is a destructive fibro-inflammatory disease of the pancreas,
increases the risk of developing pancreatic cancer (Whitcomb et al.,
2004). Indeed, CP patients have an overall 16-fold higher risk
of developing PDAC compared to unaffected individuals (Rivera
et al., 1997). Histologically, there are many features such as fibro-
sis, desmoplasia and immune cell infiltration that are observed
in both PDAC and CP (Bai et al., 2011; Ino et al., 2013). The con-
tribution of CP to PDAC is highlighted by the observation that
activation of K-RasG12V in acinar/centroacinar cells in adult mice
(mimicking the occurrence of activating KRAS mutations arising in
adult humans) necessitates the induction of pancreatitis in order
to induce PanIN lesions and cancer (Guerra et al., 2007; Zhang
et al., 2013). Oxidative stress is a well recognised feature of CP
which is evidenced by the findings of increased in lipid perox-
idation products in the pancreatic juice and circulating plasma
of CP patients (Ganesh et al., 1999; Stevens et al., 2012) and
elevated pancreatic tissue DNA oxidation in rodent CP models
(Zeki et al., 2002). Several mechanisms are known to contribute
to the perturbed redox status found in CP, such as free radical
production during alcohol metabolism (Altomare et al., 1996), ER
stress (Sah et al., 2014) and ROS production by locally activated
immune cells (O’Byrne and Dalgleish, 2001). Within the proin-
flammatory state found in CP, increased expression of Nrf2 and
phase II antioxidant enzymes (NQO1, HO-1) have been shown to be
present, inferring cytoprotection (Yang et al., 2012). The problem
appears to arise when oncogenic K-Ras is also present, as pan-
creatic tissue injury repair is compromised (Zhang et al., 2013).
Pancreatitis in the context of oncogenic K-Ras drives progression
of acinar-ductal metaplasia into progressive PanIN lesions, rather
than normal re-differentiation into acinar cells (Zhang et al., 2013).
PanIN progression appears to be augmented by Nrf2 activity, with
failure to upregulate Nrf2 resulting in increased tumour cell death
(Zhang et al., 2013; DeNicola et al., 2011). Interestingly, Zhang et al.
suggest that oncogenic Nrf2 activation by K-Ras may  be depend-
ent on Interleukin-6, and that these factors, together with STAT3
activation (Lesina et al., 2011), are required for PanIN progression
to PDAC (Zhang et al., 2013).
3.5. Variable Nrf2, Keap1 and ARE-target gene expression across
PDAC cell lines
Across pancreatic cancer cell lines, there is variability in basal
Nrf2 protein expression (see Table A1). Hong et al. found Nrf2
to be over-expressed in several PDAC cell lines (Panc-1, AsPC-
1, Colo-357), when compared to normal human pancreatic duct
epithelial cells (Hong et al., 2010). Surprisingly, other PDAC cell
lines which also have mutant KRAS, namely MiaPaCa-2 or FAM-
PAC, have low levels of basal Nrf2 protein (Lister et al., 2011).
Additionally, reported basal Nrf2 protein levels in the Panc-1 cell
line have been variable, as detected by immunoblot (Hong et al.,
2010; Lister et al., 2011; Arlt et al., 2013). With regard to Keap1,
basal levels were reported as consistently elevated across PDAC cell
lines, with the exception of Suit-2 (Lister et al., 2011). Perhaps not
unsurprisingly, there also exists variability in the ARE-target gene
expression amongst PDAC cell lines. This is most clearly demon-
strated when considering differences between Panc-1 and AsPC-1
cells. The former have elevated Nrf2 expression but low NQO1
and GCLC levels, whilst AsPC-1 cells have much lower Nrf2 lev-
els but high NQO1 expression (Hong et al., 2010). Whilst NQO1
is commonly over-expressed in the majority of PDAC cell lines
(BxPC3, Capan1, MiaPaCa-2, AsPC-1) (Cullen et al., 2003), Panc-1, is
unusual in this regard as it contains homogenous expression of the
NQO1*2 polymorphism, resulting in repressed expression (Siegel
et al., 2012). Nrf2 knockdown reduces NQO1 and GCLC in AsPC-
1 cells, supporting the notion of Nrf2-driven expression of these
target genes in this line (Duong et al., 2014). For a thorough inves-
tigation of the downstream effects of Nrf2 repression and activation
in the AsPC-1 cell line, see a recent report by Yi and Oh,  2015.
Taking these findings together, it appears that basal activity of the
Nrf2–ARE system is commonly upregulated in different PDAC cell
lines, and that differences in ARE-target protein expression may
arise not solely from upstream Keap1/Nrf2 dysregulated activity,
but also from silencing gene polymorphisms and additional factors
outwith the Keap1–Nrf2 pathway.
3.6. The effects of suppressing Nrf2 compared to Nrf2/ARE effector
proteins in PDAC
To study the effects of down regulating the Nrf2/ARE path-
way in PDAC, some investigators have targeted individual enzymes
that are members of the ARE-gene battery, whilst others have
repressed Nrf2. Of course, with the latter approach, multiple cyto-
protective and proteasomal genes would be affected given that the
function of Nrf2 is to regulate transcription of the large portfo-
lio of ARE-regulated genes. The studies reviewed here employed
several techniques to suppress Nrf2 or ARE-target protein activ-
ity; the specific use of Nrf2 inhibitors in PDAC is discussed later.
Proliferation and apoptosis of PDAC cell lines following Nrf2/ARE
suppression, including resistance to chemotherapy compounds,
have been the major outcomes reported, but proteasome activ-
ity has also been assessed in Nrf2 knockdown (Arlt et al., 2013).
The effects of Nrf2/ARE inhibition in PDAC have been investi-
gated both in vitro (Chung et al., 2012; Duong et al., 2014; Nolan
et al., 2007; Reigan et al., 2007; Dehn et al., 2006; Lister et al.,
2011) and in vivo (Duong et al., 2014; Dehn et al., 2006; Lewis
et al., 2004; Li et al., 2011; Ough et al., 2005; Zhang et al., 2014).
The majority of in vivo studies have used MiaPaca-2 xenografts,
wherein cancer cells were injected into the spleen (Li et al.,
2011) or subcutaneously (Duong et al., 2014; Dehn et al., 2006;
Lewis et al., 2004; Ough et al., 2005). Less frequently, Colo-357,
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Panc-1 and CD18 subcutaneous xenograft tumour models have also
been studied (Arlt et al., 2013; Zhang et al., 2014). Given the possible
confounding off-target effects of inhibitor compounds, compar-
isons between Nrf2 and ARE-target protein suppression in specific
cell lines are confined to those studies where RNAi knockdown was
employed, or else highly selective ARE-target protein inhibitors.
3.6.1. PDAC cell viability, chemosensitivity and proteasome
activity with Nrf2 inhibition
Nrf2 knockdown has been found to consistently reduce viability
of several PDAC cell lines, including AsPC-1, Suit-2, MiaPaCa-2 and
FAMPAC cell lines (Lister et al., 2011; Duong et al., 2014). Using an
alternative method to repress Nrf2, by PIK-75 treatment to increase
proteasomal Nrf2 degradation, increased apoptosis of AsPC-1 and
MiaPaCa-2 cells was similarly observed (Duong et al., 2014).
As for Nrf2-dependent chemoresistance, reports have been vari-
able across different PDAC cell lines. Enhanced sensitivity of AsPC-1
cells treated with cisplatin, phenethyl isothiocyanate and gemc-
itabine has been observed following Nrf2 knockdown (Ju et al.,
2015; Hong et al., 2010; Duong et al., 2014). Similarly, knockdown of
Nrf2 in Colo-357 cells resulted in reduced viability after treatment
with cisplatin and phenethyl isothiocyanate (Hong et al., 2010).
Up-regulation of Nrf2 by t-BHQ in AsPC-1 and Colo-357 cells under-
going cisplatin and camptothecin treatment increased cell survival,
and also highlights the protective role of Nrf2 (Hong et al., 2010).
In Suit-2 cells subjected to Nrf2 knockdown, enhanced sensitiv-
ity to cisplatin and gemcitabine was identified, but no discernable
change in sensitivity following 5-FU treatment (Lister et al., 2011).
Like Suit-2 cells, enhanced sensitivity to cisplatin was observed in
FAMPAC cells with Nrf2 knockdown, but contrary to the findings
in Suit-2, FAMPAC cells are found to have increased sensitivity to
5-FU but minimal response to gemcitabine sensitivity following
knockdown (Lister et al., 2011). In Panc-1 cells, Nrf2 suppres-
sion enhanced the cytotoxic effects of etoposide (Arlt et al., 2013).
Depletion of Nrf2 has been demonstrated to increase MiaPaCa-2
sensitivity to gemcitabine in vitro and in vivo, and limits the ability
of these cells to adapt to gemtamicin-induced ROS formation (Ju
et al., 2015; Duong et al., 2014).
Proteasome activity is consistently reduced following Nrf2
knockdown across PDAC cell lines (Arlt et al., 2013). This aspect
of Nrf2 signalling is important for tumorigenesis as it provides
anti-apoptotic protection and efficient clearance of irregular pro-
teins.
3.6.2. PDAC cell viability and chemosensitivity with suppression
of Nrf2/ARE downstream effector proteins
3.6.2.1. NAD(P)H:quinone oxidoreductase 1. The prototypical ARE-
target gene protein, NQO1, is a drug-metabolising enzyme
primarily located in the cytosol where it protects against ROS and
directly metabolises highly toxic and reactive quinone species, as
well as having a role in stabilising p53 (Ross et al., 2000; Nioi and
Hayes, 2004). Quinones are oxidised aromatic compound deriva-
tives, and exogenous sources include vehicle exhaust fumes and
cigarette smoke. Inhibition of NQO1 in vitro was  reported to sup-
press cell viability and the colony-forming capacity of BxPC-3
(Dehn et al., 2006) and MiaPaCa-2 cells (Cullen et al., 2003; Dehn
et al., 2006; Li et al., 2011) in a dose dependent manner, using
NQO1 inhibitors Dicumarol and 2-methyl indolequinone ES936.
The delivery of NQO1 inhibitors either directly (intra-tumoral)
(Lewis et al., 2004) or systemically (intra-peritoneal) (Dehn et al.,
2006) appears to suppress growth of MiaPaCa-2 xenograft tumous
in vivo. The dependency of NQO1 in the reported anti-proliferative
effects of Dicumarol was brought into question as the principle
cytotoxicity has since been attributed to off-target effects that
are independent NQO1 (Nolan et al., 2007; Reigan et al., 2007).
However, the more specific, mechanism-based inhibitor of NQO1,
ES936, inhibits proliferation of MiaPaca-2 cells in vitro and in vivo,
and thereby helps supports the contributory role of NQO1 in PDAC
proliferation (Dehn et al., 2006).
As for chemoresistance, the anti-cancer activity of a naturally
occurring quinone, !-Lapachone, which is an NQO1 substrate that
is recognised as having antineoplastic properties, was ameliorated
by NQO1 knockdown in MiaPaCa-2 cells (Ough et al., 2005). Addi-
tionally, Lewis et al. observed a reduction in the cytotoxic effects
with treatment with the quinone streptonigrin to MiaPaCa-2 cells
after Dicumarol, a rescue effect that was  absent in CaCo-2 cells; the
latter being a colon cancer cell line with low basal NQO1 expres-
sion (Lewis et al., 2005; Siegel et al., 2012). To our knowledge, use
of the more selective NQO1 inhibitor, ES396, has not been reported
in chemotherapy sensitivity experiments. However, studies to date
suggest that the antioxidant and detoxification properties of NQO1
are likely utilised by PDAC cells to promote proliferation as well as
to resist apoptosis and the cytotoxic effects of anti-cancer xenobi-
otics.
The majority of NQO1 suppression experiments in PDAC have
utilised the MiaPaca-2 cell line. To compare the effects of Nrf2
knockdown to NQO1 suppression, we can consider the findings
of Lister et al. who transfected MiaPaca-2 cells with Nrf2 siRNA.
Here, a significant reduction in proliferation on Nrf2 knockdown
compared to RNAi control was  observed (Lister et al., 2011). As
for chemosensitivity, increased apoptosis has been observed with
Nrf2 knockdown in MiaPaca-2 cells treated with the anti-cancer
agent etoposide (Arlt et al., 2013). Therefore, both targeted sup-
pression of NQO1, and its upstream regulator, Nrf2, act to promote
proliferation and chemoresistance, at least in the MiaPaca-2 cell
line.
3.6.2.2. Aldo–keto reductase family 1 member b10. Another key
Nrf2/ARE effector protein that is overexpressed in PDAC, AKR1B10,
has important detoxification functions and counters redox cycling
through catalysing the reduction of quinones (Hayes and Dinkova-
Kostova, 2014). It has a particular role in steroid metabolism
and detoxification of aldehydes. AKR1B10 silencing through siRNA
knockdown was associated with suppressed cell proliferation and
increased apoptosis in the Panc10·05 cell line compared to con-
trols (Chung et al., 2012). Using a different PDAC cell line, CD18,
AKR1B10 knockdown inhibited tumour proliferation in vivo (Zhang
et al., 2014). The contribution to chemoresistance of AKR1B10 has
not been investigated in PDAC, but suppressed AKR1B10 activity
in colorectal cancer cells has been found to reduce cell viability
following treatment from cytotoxic agents (Yan et al., 2007), and
it would be likely that overexpression of AKR1B10 contributes to
chemoresistance in other cancers. We  are not aware of any reports
of Nrf2 knockdown using either of these cell lines to drawn com-
parisons, but from these studies we find that AKR1B10 contributes
to PDAC survival and proliferation even in the absence of chemical
stress from xenobiotics.
3.6.2.3. Heme oxygenase 1. The gene encoding heme oxygenase 1,
HMOX1, contains multiple ARE sequences and is highly induced by
many chemical and physical cellular stress stimuli, including those
relevant to cancer such as oxidative stress, ER stress, UV irradiation,
and hypoxia (Ryter et al., 2006). Increased expression levels of HO-
1 have been detected in many cancers, and targeted knockdown
results in significant inhibition of PDAC cell proliferation (Berberat
et al., 2005). Down regulation of HO-1 by siRNA decreased viabil-
ity of several PDAC cell lines following exposure to radiotherapy
or gemcitabine in vitro (Berberat et al., 2005). Therefore, upregu-
lation of HO-1 in PDAC also appears to confer proliferative and
chemoresistant properties.
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3.6.2.4. Thioredoxin reductase 1. Finally, the thioredoxin antiox-
idant system, which is also under Nrf2/ARE regulation, has an
important role in maintaining redox state of thiols in cellular pro-
teins (Arnér and Holmgren, 2006). Thioredoxin is overexpressed in
human pancreatic cancer specimens and PDAC cell lines (Arnold
et al., 2004; Yi and Oh, 2015), and reduced thioredoxin (through
thioredoxin reductase) is known to promote proliferation, inhibit
apoptosis, and protect cells from oxidative stress (Powis and
Montfort, 2001; Arnold et al., 2004; Yan et al., 2012). In PDAC cell
lines (i.e. MiaPaca-2, Panc-1 and BxPC-3) treatment with selec-
tive thioredoxin reductase 1 (TrxR1) inhibitors induces apoptosis
(Yan et al., 2012). To the best of our knowledge, no combina-
tion studies with TrxR1 inhibitors and standard chemotherapy
agents have been reported using PDAC cell lines. A randomised
clinical study of PDAC patients with advanced disease treated
with thioredoxin inhibitor monotherapy failed to demonstrate
improved outcomes, however considerable methodological issues
may  have obscured potential benefits of inhibiting this antioxidant
system (Ramanathan et al., 2011). Interestingly, TrxR1 may  also
regulate Nrf2 activation (Cebula et al., 2015).
Taken together, these studies demonstrate that enzymes
encoded by ARE-genes such as NQO1,  AKR1B10, HMOX1 and TXNRD1
individually provide anti-apoptotic protection of PDAC cell lines,
as did Nrf2 knockdown, in the absence of any cytotoxic treatment.
As for chemosensitivity, increased apoptosis following Nrf2 knock-
down was seen in all PDAC cell lines treated with chemotherapy
compounds but drug-specific variability was observed, especially
for Suit-2 and FAMPAC cells (Lister et al., 2011). Whilst these cell
lines both have activating mutant K-Ras,  there are differences in
basal Nrf2 and Keap1 expression that will likely alter the effects
of Nrf2 knockdown (Lister et al., 2011; Naumann et al., 1996;
Moore et al., 2001). There is limited information on chemosen-
sitivity of PDAC cells from selected inhibition of enzymes from
ARE-driven genes, but it has been demonstrated that targeted
knockdown of NQO1 and HO-1 result in increased chemosen-
sitivity (Ough et al., 2005; Berberat et al., 2005). Unlike the
selected the Nrf2/ARE effector proteins discussed, Nrf2 is also
able to modulate other important protective systems relevant to
chemoresistance such as proteasomal gene expression and multi-
drug-resistance associated protein transporters (MRPs), providing
additional cytoprotective functions compared with increased levels
of individual drug detoxification and antioxidant proteins (Duong
et al., 2014; Hong et al., 2010; Mohelnikova-Duchonova et al.,
2013).
3.7. Nrf2 inhibitor therapy for pancreatic cancer
3.7.1. Nrf2 inhibitors
In view of the role of Nrf2 in pancreatic carcinogenesis and
chemoresistance, a strategy for selectively inhibiting Nrf2 would
appear to have potential therapeutic promise. Indeed, this is a pro-
posed approach for a variety of other common cancers (e.g. lung,
colon, head and neck, breast, and endometrial) as well as some
non-neoplastic diseases (Copple, 2012). To date, there is a small but
growing number of Nrf2 inhibitor compounds, all of which are nat-
urally occurring, namely; retinoic acid (Wang et al., 2007), brusatol
(Ren et al., 2011; Olayanju et al., 2015), luteolin (Tang et al., 2011),
and trigonelline (Boettler et al., 2011). The latter two have been
studied in pancreatic cancer.
From an investigation of a panel of flavonoids, luteolin (3′,4′,5′,7-
tetrahydroxyflavone) was uniquely identified as a potent Nrf2
inhibitor, through its ability to enhance Nrf2 mRNA decay (Tang
et al., 2011). As such, luteolin suppressed Nrf2-target gene expres-
sion in a dose-dependant manner (Tang et al., 2011). Additionally,
luteolin is recognised for its ability to inhibit PDAC cell line pro-
liferation (Cia et al., 2012; Johnson and Gonsalez de Mejia, 2013)
and recently was  shown to augment the apoptotic effect of gemc-
itabine in vivo when administered in combination (Johnson et al.,
2015). It is important to note, however, that luteolin is not a specific
Nrf2 inhibitor, and the anti-cancer effects seen in PDAC are likely
related to the impact luteolin has on several signalling pathways.
Besides Nrf2 regulation, luteolin can dramatically alter cell cycle
control and induce apoptosis through cyclooxygenase-2, NF"B, and
Bcl-xL (B-cell lymphoma-extra large) due to its core flavone chem-
ical structure (Wenzel et al., 2000). Luteolin has also been shown
to specifically inhibit other key pathways involved in angiogenesis,
proliferation and inflammation through reduced vascular endothe-
lial growth factor (Bagli et al., 2004; Cai et al., 2012), inhibited JNK
(c-Jun N-terminal kinase)  and AP-1 (activator protein 1) signalling
(Jang et al., 2008), STAT3 degradation (Selvendiran et al., 2006),
and p53 stabilisation (López-Lázaro, 2009). The studies of luteolin
presented to date in PDAC cell lines did not specifically determined
whether the pro-apoptotic effects of luteolin were dependent upon
Nrf2 inhibition (Cai et al., 2012; Johnson and Gonsalez de Mejia,
2013; Johnson et al., 2015).
Trigonelline (1-methylpyridinium-3-carboxylate), a major alka-
loid coffee bean extract, was  first reported as an inhibitor of
Nrf2/ARE dependent gene expression in colon cancer cells (Boettler
et al., 2011). More recently, trigonelline has been tested in PDAC cell
lines where it was found to inhibit the ability of Nrf2 to translo-
cate into the nucleus (Arlt et al., 2013). Importantly, the sensitivity
of PDAC cells to anti-cancer drugs was increased with trigonelline
treatment (Arlt et al., 2013). In this study, the suppression of pro-
teasomal activity by trigonelline in PDAC cell lines was  clearly
demonstrated to be dependent upon Nrf2 by using a targeted
knockdown approach (Arlt et al., 2013). The greatest inhibitory
effects of trigonelline upon Nrf2/ARE signalling in both pancreatic
and colon cancer cells were at submaximal doses, with higher lev-
els being less efficient or ineffective (Arlt et al., 2013; Boettler et al.,
2011).
In non-PDAC cancer studies, brusatol has been shown to be a
highly specific Nrf2 inhibitor which produces rapid and transient
effects, and can increase chemotherapy sensitisation (Olayanju
et al., 2015; Ren et al., 2011). Thus brusatol would be a useful
experimental tool for further study of Nrf2 in PDAC, although
the precise mechanism of Nrf2 inhibition is still under investiga-
tion. The Nrf2/ARE suppressive effects of retinoic acid have been
shown to be mediated through direct binding to Nrf2 by retinoic
X receptor alpha in the nucleus, a mechanism which augments
cancer cell chemosensitivity and may  also be useful for study-
ing Nrf2 inhibition in PDAC (Wang et al., 2007; Valenzuela et al.,
2014).
Although complicated by dosing considerations, Nrf2 inhibitors
provide useful tools in exploring the mechanisms and effects of
Nrf2 inhibition in the preclinical setting, from which assessments
can be made as to the therapeutic context that these might be
safely be applied to PDAC and other diseases with Keap1–Nrf2
dysregulation (Chapple et al., 2012; Copple, 2012; Olayanju et al.,
2015).
3.7.2. Challenges in the application of Nrf2 inhibitor therapy for
pancreatic cancer
The study of Nrf2 inhibitors in pancreatic cancer models
prompts consideration of how Nrf2 targeted therapies could be
safely and effectively applied to PDAC patients. Notwithstanding
the issues of patient selection and of delivering relevant drug
concentrations to the cancer tissues, there remain two partic-
ular difficulties which may  preclude the use of targeted Nrf2
inhibitors for PDAC which relate to the suppression of Nrf2 in
non-cancerous host tissue. Firstly, there may  be an intolerable
or unacceptable side-effect profile when using anti-cancer cyto-
toxic drugs in combination with Nrf2 inhibitor therapy, as a result
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Fig. A1. Overview of the Keap1–Nrf2–ARE system. The schematic illustrates that under normal homeostatic conditions (basal state), Nrf2 is prevented from associating
with  the antioxidant response element (ARE) since the Nrf2 protein is targeted by Cullin-3 (Cul3) for proteasomal degradation by Keap1. Under conditions of cellular stress
(induced  state), cysteine residues on Keap1 are modified by oxidants and electrophiles, impeding the binding of Nrf2 which is free to translocate to the nucleus. Inside
the  nucleus, Nrf2 forms a heterodimer with small Maf  protein (sMaf) and activates transcription of selected genes, such as NQO1 and AKR1C1, which contain the ARE gene
promoter region.
suppressed cytoprotective systems in non-target cells. Secondly,
there is at present little known of the effects that modulat-
ing Nrf2–ARE signalling might have upon interactions between
tumour metastasis and the host, which may  alter the bio-
logical behaviour of the metastasis. Indeed, there is evidence
that Nrf2 may  be protective against cancer metastasis (Satoh
et al., 2010). Further preclinical investigation into the mechanistic
role of Nrf2 in PDAC metastasis would clearly be impor-
tant.
4. Conclusions
Nrf2 is frequently upregulated in PDAC and is at least in part,
likely to be oncogene driven, and contributes to proliferation
and chemoresistance. Raised Nrf2 levels in PDAC occur in the
absence of somatic gene mutations in NFE2L2 or its dominant nega-
tive regulator, KEAP1.  Of prognostic importance, increased tumour
nuclear Nrf2 expression correlates with reduced survival. Targeted
Nrf2 inhibitors have been found to be therapeutically beneficial
when administered in combination with conventional anti-cancer
drugs in preclinical PDAC studies by increasing chemosensitiv-
ity. The introduction of Nrf2 inhibitors into the clinical setting
for pancreatic cancer is a promising avenue but presents some
challenges.
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Appendix A.
Fig. A2. Downstream functions of the Nrf2–ARE pathway. Nrf2 inhibits lipid and
glucose synthesis, and activates several cytoprotective mechanisms which serve to
prevent or control cellular damage and activate repair and regeneration.
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Fig. A3. Keap1–Nrf2 signalling in pancreatic cancer. The schematic illustrates oncogene-driven NFE2L2 transcription in pancreatic cancer (A), resulting in high levels of Nrf2
protein  being translated (B). Whilst a proportion of Nrf2 protein will continue to be degraded via Keap1-mediated ubiquitination by Cul3 (C), the much increased NFE2L2
transcription results in greater availability of Nrf2 protein to translocate into the nucleus (D), which results in heterodimerization with small Maf protein and upregulation of
ARE-driven gene transcription. In this way, cancer cells can gain several selective advantages including increased proliferation, enhanced drug detoxification, and improved
redox  homeostasis by increased scavenging of reactive oxygen species (ROS).
Table A1
Basal protein expression levels of Nrf2, Keap1, and downstream Nrf2/ARE effector proteins (NQO1, AKR1B10, AKR1C1) across commonly used pancreatic cancer cell lines
compared with mutant KRAS status.
Cell line Nrf2 protein Keap1
protein
Nrf2/ARE effector proteins Activating mutation
NQO1 AKR1B10 AKR1C1 KRAS
AsPC-1 High (Hong et al., 2010) – High (Hong et al., 2010;
Cullen et al., 2003; Lewis
et al., 2004)
– – Mutant (Moore et al., 2001;
Loukopoulos et al., 2004)
BxPC-3 – – High (Cullen et al., 2003;
Dehn et al., 2006; Lewis
et  al., 2004)
– – WT (Loukopoulos et al., 2004;
Naumann et al., 1996;
Berrozpe et al., 1994)
Capan-1 High (Hong et al., 2010) – High (Cullen et al., 2003) High (Chung
et al., 2012)
Mutant (Loukopoulos et al.,
2004; Naumann et al., 1996;
Berrozpe et al., 1994)
Colo-357 High (Hong et al., 2010;
Arlt et al., 2013)
– High (Hong et al., 2010) – – Mutant (Naumann et al., 1996)
FAMPAC Undetected (Lister et al.,
2011)
High (Lister
et al., 2011)
– – Low (Lister
et al., 2011)
Mutant (Fredebohm et al.,
2012)
MiaPaca-2 Undetected (Lister et al.,
2011).
Detected, no increase
(Arlt et al., 2013)
High (Lister
et al., 2011)
High (Cullen et al., 2003;
Dehn et al., 2006; Lewis
et  al., 2004)
– High (Lister
et al., 2011)
Mutant (Moore et al., 2001)
Panc-1 Undetected (Lister et al.,
2011).
High (Hong et al., 2010;
Arlt et al., 2013)
High (Lister
et al., 2011)
Undetected (Hong et al.,
2010)
– High (Lister
et al., 2011)
Mutant (Moore et al., 2001)
Suit-2 High (Lister et al., 2011) Low (Lister
et al., 2011)
– – High (Lister
et al., 2011)
Mutant (Moore et al., 2001)
The protein levels reported in the table reflect expression compared with controls by immunoblot. ‘WT’ is wild-type. Variability is found across pancreatic cancer cell lines
in  basal Nrf2, Keap1 and Nrf2/ARE effector protein levels. There appears to be no clear association between mutant KRAS status and expression of Nrf2 and ARE-target genes,
which  suggests that additional factors outwith the Keap1–Nrf2 pathway contribute significantly.
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